Drugs & Clinical Trials | By October 14, 2008 | By Jennifer Gibson, PharmDcloseJennifer Gibson, PharmD Name: Jennifer Gibson
Site: http://brainblogger.com
See All Articles by Author (73)
About: Jennifer Gibson, PharmD, is a practicing clinical pharmacist and freelance medical writer and editor with experience in researching and preparing scientific publications, developing public relations materials, creating educational resources and presentations, and editing technical manuscripts. Her clients include academic research institutions, international authors, pharmaceutical companies, professional organizations, and public advocacy groups. | 1 Comment

Hope for Huntington’s Disease – Xenazine for Chorea

Huntington’s Disease (HD) is a fatal, inherited neurodegenerative disease. It affects approximately 30,000 people in the United States, with another 200,000 at risk of developing the disease. There is currently no cure.

Hope is on the horizon, however, with the FDA’s approval of the first drug to treat HD in August of 2008. The drug, Xenazine (tetrabenazine) was developed in the 1950’s to treat psychosis, but had limited success. Now, it is available in the United States, as well as Europe, Canada, and Australia, to treat one of the hallmark symptoms of HD — chorea. Read more →